Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Bruno Dubois; Harald Hampel; Howard H. Feldman; Philip Scheltens; Paul Aisen; Sandrine Andrieu; Hovagim Bakardjian; Habib Benali; Lars Bertram; Kaj Blennow; Karl Broich; Enrica Cavedo; Sebastian Crutch; Jean-Francois Dartigues; Charles Duyckaerts; Stephane Epelbaum; Giovanni B. Frisoni; Serge Gauthier; Remy Genthon; Alida A. Gouw; Marie-Odile Habert; David M. Holtzman; Miia Kivipelto; Simone Lista; Jose-Luis Molinuevo; Sid E. O'Bryant; Gil D. Rabinovici; Christopher Rowe; Stephen Salloway; Lon S. Schneider; Reisa Sperling; Marc Teichmann; Maria C. Carrillo; Jeffrey Cummings; Cliff R., Jr. Jack

doi:10.1016/j.jalz.2016.02.002

Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

Bruno Dubois, Harald Hampel, Howard H. Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow, Karl Broich, Enrica Cavedo, Sebastian Crutch, Jean-Francois Dartigues, Charles Duyckaerts, Stephane Epelbaum, Giovanni B. Frisoni, Serge Gauthier, Remy Genthon, Alida A. GouwMarie-Odile Habert, David M. Holtzman, Miia Kivipelto, Simone Lista, Jose-Luis Molinuevo, Sid E. O'Bryant, Gil D. Rabinovici, Christopher Rowe, Stephen Salloway, Lon S. Schneider, Reisa Sperling, Marc Teichmann, Maria C. Carrillo, Jeffrey Cummings, Cliff R., Jr. Jack

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

Original language	English
Pages (from-to)	292-323
Journal	Alzheimers & Dementia
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2016.02.002
Publication status	Published - Mar 2016

Access to Document

10.1016/j.jalz.2016.02.002

Cite this

Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., Broich, K., Cavedo, E., Crutch, S., Dartigues, J-F., Duyckaerts, C., Epelbaum, S., Frisoni, G. B., Gauthier, S., Genthon, R., ... Jack, C. R. . J. (2016). Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers & Dementia, 12(3), 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

@article{6bc70f5e32b6492ca4e5bf5c13e28764,

title = "Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria",

abstract = "During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.",

keywords = "Alzheimer's disease, Preclinical, Asymptomatic, Diagnostic criteria, Biomarkers, Pathophysiology, Genetics, CSF biomarkers, Blood biomarkers, MRI, Amyloid PET, Tau PET",

author = "Bruno Dubois and Harald Hampel and Feldman, {Howard H.} and Philip Scheltens and Paul Aisen and Sandrine Andrieu and Hovagim Bakardjian and Habib Benali and Lars Bertram and Kaj Blennow and Karl Broich and Enrica Cavedo and Sebastian Crutch and Jean-Francois Dartigues and Charles Duyckaerts and Stephane Epelbaum and Frisoni, {Giovanni B.} and Serge Gauthier and Remy Genthon and Gouw, {Alida A.} and Marie-Odile Habert and Holtzman, {David M.} and Miia Kivipelto and Simone Lista and Jose-Luis Molinuevo and O'Bryant, {Sid E.} and Rabinovici, {Gil D.} and Christopher Rowe and Stephen Salloway and Schneider, {Lon S.} and Reisa Sperling and Marc Teichmann and Carrillo, {Maria C.} and Jeffrey Cummings and Jack, {Cliff R., Jr.}",

year = "2016",

month = mar,

doi = "10.1016/j.jalz.2016.02.002",

language = "English",

volume = "12",

pages = "292--323",

journal = "Alzheimers & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "3",

}

Dubois, B, Hampel, H, Feldman, HH, Scheltens, P, Aisen, P, Andrieu, S, Bakardjian, H, Benali, H, Bertram, L, Blennow, K, Broich, K, Cavedo, E, Crutch, S, Dartigues, J-F, Duyckaerts, C, Epelbaum, S, Frisoni, GB, Gauthier, S, Genthon, R, Gouw, AA, Habert, M-O, Holtzman, DM, Kivipelto, M, Lista, S, Molinuevo, J-L, O'Bryant, SE, Rabinovici, GD, Rowe, C, Salloway, S, Schneider, LS, Sperling, R, Teichmann, M, Carrillo, MC, Cummings, J & Jack, CRJ 2016, 'Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria', Alzheimers & Dementia, vol. 12, no. 3, pp. 292-323. https://doi.org/10.1016/j.jalz.2016.02.002

TY - JOUR

T1 - Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

AU - Dubois, Bruno

AU - Hampel, Harald

AU - Feldman, Howard H.

AU - Scheltens, Philip

AU - Aisen, Paul

AU - Andrieu, Sandrine

AU - Bakardjian, Hovagim

AU - Benali, Habib

AU - Bertram, Lars

AU - Blennow, Kaj

AU - Broich, Karl

AU - Cavedo, Enrica

AU - Crutch, Sebastian

AU - Dartigues, Jean-Francois

AU - Duyckaerts, Charles

AU - Epelbaum, Stephane

AU - Frisoni, Giovanni B.

AU - Gauthier, Serge

AU - Genthon, Remy

AU - Gouw, Alida A.

AU - Habert, Marie-Odile

AU - Holtzman, David M.

AU - Kivipelto, Miia

AU - Lista, Simone

AU - Molinuevo, Jose-Luis

AU - O'Bryant, Sid E.

AU - Rabinovici, Gil D.

AU - Rowe, Christopher

AU - Salloway, Stephen

AU - Schneider, Lon S.

AU - Sperling, Reisa

AU - Teichmann, Marc

AU - Carrillo, Maria C.

AU - Cummings, Jeffrey

AU - Jack, Cliff R., Jr.

PY - 2016/3

Y1 - 2016/3

N2 - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

AB - During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.

KW - Alzheimer's disease

KW - Preclinical

KW - Asymptomatic

KW - Diagnostic criteria

KW - Biomarkers

KW - Pathophysiology

KW - Genetics

KW - CSF biomarkers

KW - Blood biomarkers

KW - MRI

KW - Amyloid PET

KW - Tau PET

U2 - 10.1016/j.jalz.2016.02.002

DO - 10.1016/j.jalz.2016.02.002

M3 - Article

VL - 12

SP - 292

EP - 323

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 3

ER -